Exploration of the diagnostic value and molecular mechanism of miR-1 in prostate cancer: A study based on meta-analyses and bioinformatics
ZU-CHENG XIE¹, JIA-CHENG HUANG¹, LI-JIE ZHANG², BIN-LIANG GAN³, DONG-YUE WEN², GANG CHEN², SHENG-HUA LI¹ and HAI-BIAO YAN¹
Departments of ¹Urological Surgery, ²Pathology and ³Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Received December 17, 2017; Accepted September 24, 2018
DOI: 10.3892/mmr.2018.9598

Abstract. Prostate cancer (PCa) remains a principal issue to be addressed in male cancer-associated mortality. Therefore, the present study aimed to examine the clinical value and associated molecular mechanism of microRNA (miR)-1 in PCa. A meta-analysis was conducted to evaluate the diagnosis of miR-1 in PCa via Gene Expression Omnibus and ArrayExpress datasets, The Cancer Genome Atlas miR-1 expression data and published literature. It was identified that expression of miR‑1 was significantly downregulated in PCa. Decreased miR‑1 expression possessed moderate diagnostic value, with area under the curve, sensitivity, specificity and odds ratio values at 0.73, 0.77, 0.57 and 4.60, respectively. Using bioinformatics methods, it was revealed that a number of pathways, including the ‘androgen receptor signaling pathway’, ‘androgen receptor activity’, ‘transcription factor binding’ and ‘protein processing in the endoplasmic reticulum’, were important in PCa. A total of seven hub genes, including phosphoribosylaminoimidazole carboxylase and phosphoribosylaminomimidazole succinocarboxamide synthase (PAICS), cadherin 1 (CDH1), SRC proto-oncogene, non-receptor tyrosine kinase, twist family bHLH transcription factor 1 (TWIST1), ZW10 interacting kinetochore protein (ZWINT), PCNA clamp associated factor (KIAA0101) and androgen receptor, among which, five (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) were significantly upregulated and negatively correlated with miR-1, were identified as key miR‑1 target genes in PCa. Additionally, it was investigated whether miR-1 and its hub genes were associated with clinical features, including age, tumor status, residual tumor, lymph node metastasis, pathological T stage and prostate specific antigen level. Collectively the results suggest that miR-1 may be involved in the progression of PCa, and consequently be a promising diagnostic marker. The ‘androgen receptor signaling pathway’, ‘androgen receptor activity’, ‘transcription factor binding’ and ‘protein processing in the endoplasmic reticulum’ may be crucial interactive pathways in PCa. Furthermore, PAICS, CDH1, TWIST1, ZWINT and KIAA0101 may serve as crucial miR-1 target genes in PCa.

Introduction
Prostate cancer (PCa) remains the cancer with the highest incidence and third highest cause of cancer-associated mortality in males, with an estimated 161,360 new cases and 26,730 mortalities, according to 2017 statistics (1). A number of factors contribute to the survival of patients with PCa, particularly the disease stage at the time of diagnosis. Therefore, the early detection of PCa may improve clinical treatment and patient prognosis. Various techniques for the diagnosis of PCa have been developed; these include pathological biopsy, the gold standard in diagnosis, and other detection methods, including the prostate-specific antigen (PSA) assay (2-4), positron emission tomography (5), multiparametric magnetic resonance imaging (6,7), and urinary long non-coding RNA and microRNA (miRNA/miR) detection (8,9), which have also been used in clinical diagnosis. Despite progress, PCa still requires further novel diagnostic biomarkers to aid in its diagnosis.

miRNAs are known to have a crucial role in the regulation of tumor suppressor genes and oncogenes, resulting in the regulation of cell proliferation and apoptosis (10). miR-1 has been previously reported to be implicated in various tumors (11). The diagnostic value of miR-1 has been reported
in breast cancer (12), colorectal cancer (13) and prostate recurrence (14). Details of the molecular mechanisms of miR-1 in diverse cancer types have been reported over the years. For example, the HOX transcript antisense RNA-miR-1-cyclin D2 axis was reported to promote thyroid cancer cell growth, invasion and migration (15). miR-1 was revealed to suppress colorectal cancer cell proliferation by inhibiting SMAD3-mediated tumor glycolysis (16). In bladder cancer, miR-1 suppressed cell proliferation, invasion and migration by upregulating secreted frizzled-related protein 1 expression (17). miR-1 was also reported to inhibit breast cancer progression by downregulating K-ras and metastasis associated lung adenocarcinoma transcript 1 (18). Regarding PCa, Chang et al (19) identified that the epidermal growth factor receptor was able to boost PCa bone metastasis by downregulating miR-1 and activating twist-related protein 1 (TWIST1). Stope et al (20) reported that heat-shock protein β-1 reduced the expression of miR-1, which restored oncogenic pathways in PCa cells.

Despite all the studies regarding miR-1 in PCa, to the best of our knowledge, no study has examined its diagnostic significance via systematic meta-analysis and identified the potential target genes and pathways using bioinformatics methods. Therefore, it was necessary for the present study to conduct systematic meta-analysis and bioinformatics analysis to comprehensively evaluate the diagnostic value of miR-1, and examine the potential molecular modulatory mechanisms in PCa. The aim of the present study was to elucidate the diagnostic value of miR-1 in PCa in a more comprehensive way and pose a perspective into the potential molecular mechanism, which may contribute to clinical diagnosis and treatment.

In the present study, a meta-analysis using Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), ArrayExpress and data from published literature was conducted, to assess the clinical diagnostic value of miR-1 in PCa. By collecting the potential target genes of miR-1 and using bioinformatics analysis, the important targets and signaling pathways of miR-1 in PCa were identified. The present study may aid validation of the diagnostic value of miR-1 in PCa and provide insight into the theoretical molecular modulatory mechanisms for future studies.

Materials and methods

Collection of miR-1 expression data from TCGA. miRNA expression matrix was downloaded from TCGA (https://cancergenome.nih.gov/) (21). The expression data of miR-1-1 and miR-1-2 were included in the investigation. Samples missing miR-1-1 or miR-1-2 expression data were removed from the present research. All the data was normalized using log2 conversion. Additionally, mRNA data was downloaded from the portal of prostate adenocarcinoma in TCGA. The DESeq package (22) in the R program (version 3.3.0) was applied to obtain the differentially expressed genes (DEGs).

Retrieval of GEO and ArrayExpress PCa datasets. To analyze the expression level of miR-1 in PCa and non-tumor tissue, the GEO and ArrayExpress databases were searched. The key words were as follows: Prostat' and (malignan' OR cancer OR tumor OR tumour OR tumor OR neoplas' OR carcinoma). Microarray datasets that contained the miR-1 values were included. All the data in the datasets were calculated in the log2 scale for normalization. To collect DEGs in PCa following miR-1 pretreatment, the Gene Expression Omnibus (GEO) and ArrayExpress databases were additionally searched with the following retrieval strategies: Prostat' and (malignan' OR cancer OR tumor OR tumour OR neoplas' OR carcinoma) and (miR-1 OR miRNA-1-1 OR microRNA-1-1 OR miR1 OR miRNA1 OR microRNA1 OR ‘miR’ 1’ OR ‘miRNA’ 1’ OR ‘microRNA’ 1’ OR miR1-3p OR miRNA-1-3p OR microRNA-1-3p OR miR-1-1 OR miR-1-2 OR miR1-1 OR miR1-2). Microarrays containing mRNA expression following miR-1 silencing or overexpression were enrolled for further analysis.

Retrieval of published literatures. PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), Science Direct (https://www.sciencedirect.com/), Google Scholar (https://scholar.google.com/), Ovid (http://www.ovid.com), Wiley Online Library (https://onlinelibrary.wiley.com/), EMBASE (https://www.embase.com), Web of Science (https://clarivate.com/products/web-of-science/), Chong Qing VIP (http://qikan.cqvip.com/), CNKI (http://cnki.net/), Wan Fang (www.wanfangdata.com.cn) and China Biology Medicine Disc (http://www.sinomed.ac.cn/) were used for literature retrieval. The searching strategies were as follows: Prostat' and (malignan' OR cancer OR tumor OR tumour OR tumor OR neoplas' OR carcinoma) and (miR-1 OR miRNA-1-1 OR microRNA-1-1 OR miR1 OR miRNA1 OR microRNA1 OR ‘miR’ 1’ OR ‘miRNA’ 1’ OR ‘microRNA’ 1’ OR miR1-3p OR miRNA-1-3p OR microRNA-1-3p OR miR-1-1 OR miR-1-2 OR miR1-1 OR miR1-2). Studies for which the mean, standard deviation and case number of miR-1 in prostate cancer and non-tumor groups were available were further analyzed. Additionally, studies that provided the true positive, false positive, false negative and true negative values were included in the diagnostic meta-analysis.

Identification of putative miR-1 target genes. For the microarray data with silenced or overexpressed miR-1, the mRNA expression was analyzed and log2 fold change (FC) was calculated to select the DEGs. Log2 FC<0 or log2 FC>0 was adopted to screen the downregulated or upregulated genes in the miR-1 overexpressed or silenced microarrays, respectively. Additionally, DEGs were obtained from the TCGA data through the standard log2 FC>1. Furthermore, the miRWalk 2.0 tool (http://zmf.umm.uni-heidelberg.de/mirwalk2/) (23), which links to 11 other online prediction databases, was used to predict the putative target genes of miR-1. Targets predicted by more than two datasets were finally selected. Genes that were included as DEGs from the GEO microarrays and TCGA, and the predicted target genes, were filtered further to collect the more specific target genes of miR-1. Finally, the validated target genes reported in the published literature were included in the genes for further analysis.

Bioinformatics analysis. To uncover the potential crucial signal pathways and target genes of miR-1 in PCa, Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway analysis were performed using DAVID 6.8 (david-d.ncifcrf.gov/). \( P<0.05 \) was considered to indicate a statistically significant difference. The false discovery rate was adopted to reflect the rate of type I errors in multiple comparisons. A protein-protein interaction (PPI) network was plotted using the plugin stringAPP 1.10 in Cytoscape 3.50 (http://www.cytoscape.org/) (24), which has the ability to import the network from the STRING (string-db.org) database. Connection degrees >3 among the nodes were used to select the hub genes.

**Validation of the hub genes.** GEPIA (gepia.cancer-pku.cn), a newly developed interactive web server, was designed to analyze the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from the TCGA and the GTEx projects using a standard processing pipeline (25). Thus, GEPIA was used to validate the expression of the hub genes that were selected in the PPI. As miR-1 exerts its functions by specifically binding to its target genes, a Spearman’s correlation analysis was conducted to validate the correlation between miR-1 and hub genes. The expression data of miR-1 and hub genes was downloaded from TCGA database. The expression data of miR-1 in TCGA included miR-1-1 and miR-1-2; therefore, the average expression of miR-1-1 and miR-1-2 was calculated to represent the expression of miR-1. The expression data of miR-1 and hub genes were normalized with log2 (x+1).

**Clinical value of miR-1 and hub genes in PCa.** The data of miR-1, hub genes and clinical phenotype of PCa were obtained from TCGA database. The information of age, cancer status, residual tumor, Tumor, Node, Metastasis stage, survival time, final status, PSA level, hormone therapy and drug response were collected. The expression of miR-1, hub genes and PSA value were normalized with log2 (x+1). The expression difference analysis of miR-1, phosphoribosylaminomimidazole carboxylase and phosphoribosylaminomidadoleuccinocarboxamide synthase (PAICS), cadherin 1 (CDH1), SRC proto-oncogene, non-receptor tyrosine kinase (SRC), twist family bHLH transcription factor 1 (TWIST1), ZW10 interacting kinetochore protein (ZW10), ZWINT, PCNA clamp associated factor (KIAA0101) and androgen receptor (AR) among AR-dependent, castrate-resistant (AR-independent) PCa and normal tissues were performed. The correlation among miR-1, upregulated hub genes (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) and PSA was investigated. The association between miR-1, upregulated hub genes (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) and clinicopathological parameters was investigated using SPSS 23.0 (IBM Corp., Armonk, NY, USA).

**Statistical analysis.** The standard mean deviation (SMD) was used to evaluate the miR-1 expression differences between PCa and adjacent normal tissues via continuous variable meta-analysis in Stata 14.0 (StataCorp LLC, College Station, TX, USA). The fixed effects model was adopted to analyze the SMD if there was no heterogeneity among the included studies (I²>50; \( P<0.05 \)). Otherwise, the random effects model was used. Begg and Deeks funnel plots were applied to test the publication bias of the included studies. Additionally, a sensitivity analysis was performed to demonstrate the influence of individual studies on the whole dataset. Summary receiver operating characteristic (SROC) curves, Fagan plots and forest plots of sensitivity, specificity, positive likelihood ratios, negative likelihood ratios, diagnostic scores, in addition to odds ratios depicted through Stata 14.0 (StataCorp LLC), were performed to comprehensively evaluate the diagnostic value of miR-1 in PCa. Furthermore, bivariate boxplots and likelihood matrices were plotted to illustrate the sensitivity, specificity, positive likelihood ratio and negative likelihood ratio in a plane coordinate system. SPSS 23.0 (IBM Corp.) and GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA) were used for the clinicopathological parameter analysis and to display the results, respectively. Spearman’s correlation analysis was used to analyze the correlation among miR-1, hub genes and PSA level. Student’s t test was applied for comparison of two groups and the log-rank test was used for the survival analysis. \( P<0.05 \) was considered to indicate a statistically significant difference.

**Results**

**Expression level of miR-1 in PCa.** For all the included studies, the combined SMD was -0.31 [95% confidence interval (CI), -0.60 to 0.22] based on the random effects model (I²=87.8%; Fig. 1). Publication bias was not observed in the funnel plots, as it was basically symmetrical (Fig. 2). Significant heterogeneity was observed in the forest plot. As a result, a sensitivity analysis was performed, and it was considered that GSE54516 may cause heterogeneity (Fig. 3). Following removal of GSE54516, the combined SMD was -0.31 [95% confidence interval (CI), -0.58 to 0.22] based on the random effects model (I²=56.3%; Fig. 4). Publication bias was not observed in the funnel plots, as it was basically symmetrical (Fig. 5).
-0.42 (95% CI, -0.52 to -0.32) with an $I^2=80.4\%$, which indicated downregulation (Fig. 4).

**Diagnostic value of miR-1 in PCa.** An SROC curve was used to evaluate the pooled diagnostic value of miR-1 in the included studies. The SROC curve demonstrated that the pooled area under the curve (AUC) was 0.73 (95% CI, 0.69 to 0.77; Fig. 5), which suggested a moderate diagnostic efficacy of miR-1 in PCa. The combined sensitivity and specificity were 0.77 (95% CI, 0.62 to 0.88) and 0.57 (95% CI, 0.41 to 0.72), respectively (Fig. 6). The positive diagnostic likelihood ratio (DLR) and negative DLR were 1.82 (95% CI, 1.36 to 2.43) and 0.40 (95% CI, 0.26 to 0.60), respectively (Fig. 7). The diagnostic score and odds ratios were also calculated and were 1.53 (95% CI, 0.97 to 2.08) and 4.60 (95% CI, 2.63 to 8.04), respectively (Fig. 8). A Fagan plot was used to demonstrate how much the result on the diagnostic test alters the probability that a patient has PCa. The positive and negative posterior probabilities were 31 and 9%, respectively, and the pre-test probability was 20%. (Fig. 9). Deek's funnel plot was created to check for the potential publication bias of included studies. As demonstrated in Fig. 10, the Deek's funnel plot obtained a P-value of 0.85, which suggested there was no publication bias in the diagnostic meta-analysis. A bivariate boxplot was additionally constructed to assess distributional properties of sensitivity vs. specificity and to identify potential outliers (Fig. 11). An index test was used to display informativeness of measured test, which displayed the distribution of positive and negative likelihood ratio in the diagnostic meta-analysis (Fig. 12). Collectively, no publication bias...
existed in the present study and downregulated miR-1 demonstrated moderate diagnostic accuracy in PCa.

Collection of possible target genes. In the GEO microarray datasets, GSE26032 and GSE31620, which included transfection of pre-miR oligos in prostate carcinoma cell lines to overexpress, were finally included. The expression data of the genes was extracted and the log_{2}FC was calculated. With the standard log_{2}FC<0, the downregulated genes were collected. A total of 1,239 genes were finally gathered following intersecting the downregulated genes in GSE26032 and GSE31620, which contained two and three paired samples, respectively. For TCGA DEGs, the log_{2}FC>1 was restricted and 684 genes were obtained. Furthermore, 10,025 predicted target genes were gathered using the 12 online prediction tools. To improve the specificity of the putative target genes of miR-1, the GEO downregulated genes were intersected, TCGA DEGs, in addition to the predicted genes, and 45 putative significant genes were finally obtained for further bioinformatics analysis (Table I).

Figure 6. Sensitivity and Specificity Forest plots. Vertical dotted lines represent combined sensitivity and specificity. CI, confidence interval; PMID, PubMed ID; TCGA, The Cancer Genome Atlas.

Figure 7. Positive likelihood ratio and negative likelihood ratio forest plots. Vertical dotted lines represent combined positive likelihood and negative likelihood. DLR, diagnostic likelihood ratio; CI, confidence interval; PMID, PubMed ID; TCGA, The Cancer Genome Atlas.
A total of 45 promising overlapping target genes were collected for the bioinformatics analysis (Table II; Fig. 13). The GO annotation elucidated that the promising target genes of miR-1 were closely associated with ‘the response to the drug’, ‘adherens junction organization’ and ‘androgen receptor signaling pathway’ in the ‘biological process’ (BP) domain. For the ‘cellular component’ (CC) domain, the promising miR-1 targets were mostly associated with the ‘perinuclear region of cytoplasm’, ‘extracellular exosome’ and ‘membrane’. In the ‘molecular function’ (MF) domain, the putative miR-1 targets were mostly enriched in the ‘androgen receptor activity’, the ‘transcription factor binding’ and ‘cadherin binding involved in cell-cell adhesion’.

In addition, the KEGG pathway analysis demonstrated that the ‘protein processing pathway in the endoplasmic reticulum’ was the most significant. Using the PPI network, the construction of seven hub genes (PAICS, CDH1, SRC, TWIST1, ZWINT, KIAA0101 and AR) were identified to act as the potential key targets of miR-1 in PCa (Fig. 14).

Validation of the hub genes. The expression of the seven hub genes (PAICS, CDH1, SRC, TWIST1, ZWINT, KIAA0101 and AR) was analyzed in the PCa and adjacent normal samples from TCGA and GTEx. A total of 492 PCa and 152 normal tissue samples were enrolled in the expression validation. Among the seven hub genes, it was observed that five of

Bioinformatics analysis. A total of 45 promising overlapping target genes were collected for the bioinformatics analysis (Table II; Fig. 13). The GO annotation elucidated that the promising target genes of miR-1 were closely associated with ‘the response to the drug’, ‘adherens junction organization’ and ‘androgen receptor signaling pathway’ in the ‘biological process’ (BP) domain. For the ‘cellular component’ (CC) domain, the promising miR-1 targets were mostly associated with the ‘perinuclear region of cytoplasm’, ‘extracellular exosome’ and ‘membrane’. In the ‘molecular function’ (MF)
Figure 11. Bivariate boxplot evaluating the sensitivity and specificity in a plane coordinate system. Logit transforms of sensitivity and specificity was used to assess distributional properties of sensitivity vs. specificity and to identify possible outliers. The mean logit sensitivity and specificity with their standard errors and 95% confidence intervals is presented in the gray area. SENS, sensitivity; SPECS, specificity.

Figure 12. Likelihood matrix evaluating the positive likelihood ratio and negative likelihood ratio in a plane coordinate system. Plot was divided into quadrants based on strength-of-evidence thresholds. Informativeness of measured test was used to determine the distribution of positive and negative likelihood ratio in our diagnostic meta-analysis. LUQ, left upper quadrant; RUQ, right upper quadrant; LLQ, left lower quadrant; RLQ, right lower quadrant; LRP, positive likelihood ratio; LRN, negative likelihood ratio.

Table I. 54 putative potential targets of microRNA-1.

| Gene symbol | Official name                                                                 |
|-------------|--------------------------------------------------------------------------------|
| SEL1L3      | SEL1L family member 3                                                         |
| PPM1H       | Protein phosphatase, Mg2+/Mn2+ dependent 1H                                    |
| LMNB1       | Lamin B1                                                                      |
| NKX3-1      | NK3 homeobox 1                                                                |
| SLCA4A      | Solute carrier family 4 member 4                                               |
| AP1S1       | Adaptor related protein complex 1 subunit sigma 1                             |
| PPB           | Peptidylprolyl isomerase B                                                     |
| PSAT1       | Phosphoserine aminotransferase 1                                              |
| PABPC1      | Poly(A) binding protein cytoplasmic 1                                          |
| BCAM        | Basal cell adhesion molecule (Lutheran blood group)                           |
| AGA         | Aspartylglucosaminidase                                                         |
| TMEM97      | Transmembrane protein 97                                                       |
| GALNT1      | Polypeptide N-acetylglactosaminyltransferase 1                                 |
| SEC23B      | Sec23 homolog B, coat complex II component                                     |
| GOLM1       | Golgi membrane protein 1                                                       |
| DSG2        | Desmoglein 2                                                                  |
| APLP2       | Amyloid β (A4) precursor-like protein 2                                         |
| GCNT1       | Glucosaminyl (N-acetyl) transferase 1, core 2                                  |
| EBP41L4B    | Erythrocyte membrane protein band 4.1 like 4B                                  |
| CLCN3       | Chloride voltage-gated channel 3                                               |
| PDI6        | Protein disulfide isomerase family A member 6                                  |
| SLC27A2     | Solute carrier family 27 member 2                                              |
| MYO6        | Myosin VI                                                                     |
| DSC2        | Desmocollin 2                                                                 |
| ABC4        | ATP binding cassette subfamily C member 4                                      |
| SLCA4A2     | Solute carrier family 45 member 2                                              |
| NUP210      | Nucleoporin 210                                                               |
| PAICS       | Phosphoribosylaminomimidazole carboxylase and phosphoribosyl-syalaminomidozolesuccinic-carboxamidase synthase |
| CENPF       | Centromere protein F                                                           |
| ACSL3       | Acyl-CoA synthetase long chain family member 3                                 |
| PPP3CA      | Protein phosphatase 3 catalytic subunit α                                      |
| ABHD2       | Abhydrolase domain containing 2                                               |
| NCAPD3      | Non-SMC condensin II complex subunit D                                        |
| SEL1L3      | SEL1L family member 3                                                          |
| MAP7        | Microtubule associated protein 7                                               |
| ZWINT       | ZW10 interacting kinetochore protein                                           |
| NAAA        | N-acylethanolamine acid amidase                                                |
| TUSC3       | Tumor suppressor candidate 3                                                   |
| PCLAF       | PCNA clamp associated factor                                                   |
| ETO2        | Neuropilin and tolloid like 2                                                  |
| TPD52       | Tumor protein D52                                                             |
| CDH1        | Cadherin 1                                                                    |
| CADM1       | Cell adhesion molecule 1                                                       |
| EIF2AK1     | Eukaryotic translation initiation factor 2 α kinase 1                          |
| PMEPA1      | Prostate transmembrane protein, androgen induced 1                             |

Table I. Continued.

| Gene symbol | Official name                                      |
|-------------|---------------------------------------------------|
| PNP         | Purine nucleoside phosphorylase                    |
| PTMA        | Prothymosin α                                      |
| AR          | Androgen receptor                                  |
| SRC         | SRC proto-oncogene, non-receptor tyrosine kinase   |
| TWIST1      | Twist family bHLH transcription factor 1           |
| Slug        | Snail family transcriptional repressor 2          |
| KLF4        | Kruppel like factor 4                             |
| XPO6        | Exportin 6                                        |
| TWF1        | Twinfilin actin binding protein 1                  |

Figure 11. Bivariate boxplot evaluating the sensitivity and specificity in a plane coordinate system. Logit transforms of sensitivity and specificity was used to assess distributional properties of sensitivity vs. specificity and to identify possible outliers. The mean logit sensitivity and specificity with their standard errors and 95% confidence intervals is presented in the gray area. SENS, sensitivity; SPECS, specificity.
Table II. Significant GO and KEGG pathways of the overlapping genes.

| Category          | Term                                                                 | Count | P-value   | FDR       |
|-------------------|----------------------------------------------------------------------|-------|-----------|-----------|
| GOTERM_BP_DIRECT  | GO:0042493~response to drug                                          | 6     | 0.00187   | 2.677129  |
| GOTERM_BP_DIRECT  | GO:0034332~adherens junction organization                            | 3     | 0.005205  | 7.287529  |
| GOTERM_BP_DIRECT  | GO:0030521~androgen receptor signaling pathway                        | 3     | 0.006361  | 8.837711  |
| GOTERM_BP_DIRECT  | GO:0010628~positive regulation of gene expression                    | 5     | 0.007078  | 9.786328  |
| GOTERM_BP_DIRECT  | GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules |      | 0.010974  | 14.78529  |
| GOTERM_BP_DIRECT  | GO:0086073~bundle of His cell-Purkinje myocyte adhesion involved in cell communication | 2     | 0.017384  | 22.45141  |
| GOTERM_BP_DIRECT  | GO:0044539~long-chain fatty acid import                               | 2     | 0.020252  | 25.66973  |
| GOTERM_BP_DIRECT  | GO:0014067~negative regulation of phosphatidylinositol 3-kinase signaling | 2     | 0.028808  | 34.54625  |
| GOTERM_BP_DIRECT  | GO:0006886~intracellular protein transport                            | 4     | 0.031444  | 37.07541  |
| GOTERM_BP_DIRECT  | GO:0098911~regulation of ventricular cardiac muscle cell action potential |      | 0.031644  | 37.26326  |
| GOTERM_BP_DIRECT  | GO:0071456~cellular response to hypoxia                              | 3     | 0.031963  | 37.56294  |
| GOTERM_BP_DIRECT  | GO:2000679~positive regulation of transcription regulatory region DNA binding |      | 0.042905  | 47.05066  |
| GOTERM_CC_DIRECT  | GO:0048471~perinuclear region of cytoplasm                            | 12    | 9.07E-07  | 0.001083  |
| GOTERM_CC_DIRECT  | GO:0070062~extracellular exosome                                      | 21    | 3.29E-05  | 0.039319  |
| GOTERM_CC_DIRECT  | GO:0016020~membrane                                                  | 17    | 0.000218  | 0.25958   |
| GOTERM_CC_DIRECT  | GO:0005913~cell-cell adherens junction                               | 7     | 0.000272  | 0.324715  |
| GOTERM_CC_DIRECT  | GO:0005789~endoplasmic reticulum membrane                            | 8     | 0.009743  | 11.03435  |
| GOTERM_CC_DIRECT  | GO:0016323~basolateral plasma membrane                               | 4     | 0.013947  | 15.44149  |
| GOTERM_CC_DIRECT  | GO:0032587~ruffle membrane                                           | 3     | 0.022114  | 23.45373  |
| GOTERM_CC_DIRECT  | GO:0000139~Golgi membrane                                           | 6     | 0.024307  | 25.46094  |
| GOTERM_CC_DIRECT  | GO:0031965~nuclear membrane                                         | 4     | 0.02621   | 27.17933  |
| GOTERM_CC_DIRECT  | GO:0005783~endoplasmic reticulum                                     | 7     | 0.027342  | 28.18388  |
| GOTERM_CC_DIRECT  | GO:0034663~endoplasmic reticulum chaperone complex                    | 2     | 0.030365  | 30.80375  |
| GOTERM_CC_DIRECT  | GO:0005794~Golgi apparatus                                           | 7     | 0.032588  | 32.67453  |
| GOTERM_CC_DIRECT  | GO:0016021~integral component of membrane                             | 22    | 0.032972  | 32.99373  |
| GOTERM_CC_DIRECT  | GO:0005737~cytoplasm                                                | 22    | 0.037093  | 36.3252   |
| GOTERM_MF_DIRECT  | GO:0004882~androgen receptor activity                                | 2     | 0.009037  | 12.08615  |
| GOTERM_MF_DIRECT  | GO:000134~transcription factor binding                               | 5     | 0.010545  | 12.91881  |
| GOTERM_MF_DIRECT  | GO:0098641~cadherin binding involved in cell-cell adhesion           | 5     | 0.01132   | 16.85447  |
| GOTERM_MF_DIRECT  | GO:0050839~cell adhesion molecule binding                            | 3     | 0.015076  | 19.38597  |
| GOTERM_MF_DIRECT  | GO:0008022~protein C-terminus binding                               | 4     | 0.017579  | 19.79801  |
| GOTERM_MF_DIRECT  | GO:0086083~cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication | 2     | 0.017993  | 23.42536  |
| GOTERM_MF_DIRECT  | GO:0005102~receptor binding                                         | 5     | 0.021727  | 25.48576  |
| GOTERM_MF_DIRECT  | GO:0102391~decanoate-CoA ligase activity                             | 2     | 0.02392   | 26.92366  |
| GOTERM_MF_DIRECT  | GO:0008013~β-catenin binding                                         | 3     | 0.025484  | 38.00481  |
| GOTERM_MF_DIRECT  | GO:0004467~long-chain fatty acid-CoA ligase activity                  | 2     | 0.038584  | 57.75621  |
| KEGG_PATHWAY      | hsa04141:Protein processing in endoplasmic reticulum                | 5     | 0.004469  | 10.44355  |

GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate; BP, biological process; CC, cellular component; MF, molecular function.

them (PAICS, CDH1, KIAA0101, TWIST1, and ZWINT) were significantly upregulated in PCa samples (Fig. 15A-E), which gave them more potential to be the key target genes of miR-1 in PCa. The other two hub genes (SRC and AR) did not demonstrate statistical significance between PCa and normal tissues based on the current data (Fig. 15F and G).
Spearman's correlation analysis between miR-1 and the five up-regulated hub genes (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) was performed (Fig. 16). A significant negative correlation was identified between miR-1 and PAICS, ZWINT, in addition to KIAA0101 (P<0.001; Fig. 16A-C), which supported their specific binding. Regarding CDH1 and TWIST1, a trend of negative correlation with miR-1 was observed (Fig. 16D and E). However, no statistical significance was revealed.

Clinical significance of miR-1 and hub genes in PCa. The alterations of miR-1/hub genes among 31 AR-dependent, 9 castrate-resistant PCa and 52 normal tissues were compared. For AR-dependent and castrate-resistant PCa, miR-1 was
Figure 15. Box plots for the expression of hub genes in prostate cancer and normal tissues. Box plots for the expression of (A) PAICS, (B) CDH1, (C) KIAA0101, (D) TWIST1, (E) ZWINT, (F) SRC and (G) AR. Mean and standard deviation value were calculated for the comparison. *P<0.05. PRAD, prostate adenocarcinoma; PAICS, phosphoribosylaminimidazole carboxylase and phosphoribosylaminimidazolesuccinocarboxamide synthase; CDH1, cadherin 1; SRC, SRC proto-oncogene, non-receptor tyrosine kinase; TWIST1, twist family bHLH transcription factor 1; ZWINT, ZW10 interacting kinetochore protein; KIAA0101, PCNA clamp associated factor; AR, androgen receptor; T, tumor; N, normal.

Figure 16. Correlation between miR-1 and its upregulated hub genes. Correlation between miR-1 and (A) PAICS, (B) ZWINT, (C) KIAA0101, (D) CDH1 and (E) TWIST1. Yellow area represents 95% confidence interval. miR, microRNA; PAICS, phosphoribosylaminimidazole carboxylase and phosphoribosylaminimidazolesuccinocarboxamide synthase; CDH1, cadherin 1; TWIST1, twist family bHLH transcription factor 1; ZWINT, ZW10 interacting kinetochore protein; KIAA0101, PCNA clamp associated factor.
significantly downregulated; whereas, PAICS, TWIST1, ZWINT and KIAA0101 were significantly upregulated compared with normal tissues (P<0.001; Fig. 17A and B). Regarding CDH1, SRC and AR, the expression of SRC and AR only demonstrated significant increase in AR-dependent PCa not castrate-resistant PCa, while CDH1 did not reveal any alterations in AR-dependent and castrate-resistant PCa compared with normal tissues (Fig. 17A and B). However, for comparison between AR-dependent and castrate-resistant PCa, no statistically significant expression difference of miR-1 or hub genes was observed (Fig. 17C). Further studies with larger samples are required to elucidate the alterations of PCa is the cancer type that results in the highest worldwide morbidity in the male population (1). Searching for novel diagnostic biomarkers and examining the molecular mechanisms in PCa are of great importance for its clinical diagnosis and treatment. The present study aimed to evaluate the diagnostic value of miR-1 and identify the key target genes and signaling pathways in PCa.

Using comprehensive meta-analysis of expression data from the GEO, ArrayExpress, TCGA and published literature, it was identified that the expression of miR-1 was significantly downregulated in PCa compared with the adjacent normal tissues. It was demonstrated that miR-1 has a moderate diagnostic value in PCa (AUC, 0.73; sensitivity, 0.77; specificity, 0.57; odds ratio, 4.60). To the best of our knowledge, there is only one study, conducted by Pashaei et al (26), which has identified downregulated miR-1 in recurrent PCa using a meta-analysis. However, there were only six GEO datasets included in the meta-analysis (26). A larger sample may improve the integration and conviction of the study. In the present study, 27 GEO datasets, two published studies, one ArrayExpress microarray and two sets of TCGA data were analyzed.

Based on the online prediction databases, the potential target genes of miR-1 were collected to further examine the key enriched metabolic pathways in PCa. Subsequently, GO analysis revealed the enriched pathways in three categories. In ‘BP’, the ‘response to drug’, ‘adherens junction organization’, and ‘androgen receptor signaling’ pathways were the top three pathways. In ‘CC’, the top three items were the ‘perinuclear region of the cytoplasm’, the ‘extracellular exosome’, and the ‘membrane’. In the ‘MF’, the target genes were primarily enriched in ‘androgen receptor activity’, ‘transcription
Table III. Association between miR-1/hub genes and clinicopathological parameters in prostate cancer.

### A, miR-1

| Clinicopathological feature | n | Expression (mean ± SD) | t-test | P-value |
|-----------------------------|---|------------------------|--------|---------|
| **Age (years)**             |   |                        |        |         |
| <60                         | 199| 8.759±1.229            | 1.605  | 0.109   |
| ≥60                         | 292| 8.569±1.332            |        |         |
| **Tumor status**            |   |                        |        |         |
| With tumor                  | 93 | 8.391±1.328            | -2.317 | 0.021*  |
| Tumor-free                  | 310| 8.746±1.286            |        |         |
| **Residual tumor**          |   |                        |        |         |
| No                          | 311| 8.728±1.255            | 1.836  | 0.067   |
| Yes                         | 150| 8.495±1.318            |        |         |
| **Distant metastasis**      |   |                        |        |         |
| No                          | 451| 4.617±2.286            | -4.455 | 0.000*  |
| Yes                         | 2  | 8.677±1.283            |        |         |
| **Lymph node metastasis**   |   |                        |        |         |
| No                          | 342| 8.713±1.251            | 2.764  | 0.006*  |
| Yes                         | 77 | 8.281±1.172            |        |         |
| **Pathological T**          |   |                        |        |         |
| T1 + T2                     | 186| 8.782±1.183            | 1.869  | 0.062   |
| T3 + T4                     | 298| 8.561±1.316            |        |         |

### B, PAICS

| Clinicopathological feature | n | Expression (mean ± SD) | t-test | P-value |
|-----------------------------|---|------------------------|--------|---------|
| **Age (years)**             |   |                        |        |         |
| <60                         | 199| 4.368±0.489            | 0.48   | 0.631   |
| ≥60                         | 292| 4.347±0.488            |        |         |
| **Tumor status**            |   |                        |        |         |
| With tumor                  | 93 | 4.409±0.576            | 1.156  | 0.249   |
| Tumor-free                  | 310| 4.340±0.473            |        |         |
| **Residual tumor**          |   |                        |        |         |
| No                          | 311| 4.358±0.488            | -0.153 | 0.878   |
| Yes                         | 150| 4.365±0.493            |        |         |
| **Distant metastasis**      |   |                        |        |         |
| No                          | 451| 4.350±0.486            | 1.788  | 0.075   |
| Yes                         | 2  | 4.966±0.697            |        |         |
| **Lymph node metastasis**   |   |                        |        |         |
| No                          | 342| 4.356±0.509            | 0.213  | 0.832   |
| Yes                         | 77 | 4.343±0.406            |        |         |
| **Pathological T**          |   |                        |        |         |
| T1 + T2                     | 186| 4.323±0.485            | -1.193 | 0.233   |
| T3 + T4                     | 298| 4.377±0.487            |        |         |

### C, CDH1

| Clinicopathological feature | n | Expression (mean ± SD) | t-test | P-value |
|-----------------------------|---|------------------------|--------|---------|
| **Age (years)**             |   |                        |        |         |
| <60                         | 199| 6.593±0.710            | 2.4    | 0.017*  |
| ≥60                         | 292| 6.431±0.754            |        |         |
| **Tumor status**            |   |                        |        |         |
| With tumor                  | 93 | 6.306±1.018            | -3.135 | 0.002*  |
| Tumor-free                  | 310| 6.586±0.658            |        |         |
| **Residual tumor**          |   |                        |        |         |
| No                          | 311| 6.583±0.636            | 2.967  | 0.003*  |
| Yes                         | 150| 6.338±0.912            |        |         |
| **Distant metastasis**      |   |                        |        |         |
| No                          | 451| 6.490±0.723            | -1.192 | 0.234   |
| Yes                         | 2  | 5.880±0.697            |        |         |
| **Lymph node metastasis**   |   |                        |        |         |
| No                          | 342| 6.521±0.681            | 1.185  | 0.237   |
| Yes                         | 77 | 6.409±1.003            |        |         |
| **Pathological T**          |   |                        |        |         |
| T1+T2                       | 186| 6.567±0.646            | 1.631  | 0.104   |
| T3+T4                       | 298| 6.454±0.793            |        |         |

### D, TWIST1

| Clinicopathological feature | n | Expression (mean ± SD) | t-test | P-value |
|-----------------------------|---|------------------------|--------|---------|
| **Age (years)**             |   |                        |        |         |
| <60                         | 199| 2.307±1.131            | -0.549 | 0.583   |
| ≥60                         | 292| 2.363±1.107            |        |         |
| **Tumor status**            |   |                        |        |         |
| With tumor                  | 93 | 2.404±1.198            | 1.274  | 0.203   |
| Tumor-free                  | 310| 2.240±1.056            |        |         |
| **Residual tumor**          |   |                        |        |         |
| No                          | 311| 2.271±1.067            | -1.636 | 0.103   |
| Yes                         | 150| 2.454±1.241            |        |         |
| **Distant metastasis**      |   |                        |        |         |
| No                          | 451| 2.329±1.110            | 1.444  | 0.150   |
| Yes                         | 2  | 3.463±0.032            |        |         |
| **Lymph node metastasis**   |   |                        |        |         |
| No                          | 342| 2.271±1.067            | -1.629 | 0.104   |
| Yes                         | 77 | 2.501±1.329            |        |         |
| **Pathological T**          |   |                        |        |         |
| T1+T2                       | 186| 2.200±1.053            | -2.244 | 0.025*  |
| T3+T4                       | 298| 2.434±1.154            |        |         |
factor binding’ and ‘cadherin binding in cell-cell adhesion’. Furthermore, KEGG analysis identified a significant pathway, namely ‘protein processing in the endoplasmic reticulum’. Among the above pathways discovered, it was identified that the ‘androgen receptor signaling pathway’, ‘androgen receptor activity’, ‘transcription factor binding’ and ‘protein processing in the endoplasmic reticulum’ have been previously reported. The ‘androgen receptor signaling pathway’ has been implicated in the therapeutic strategies of PCa (27-29). Regarding the ‘androgen receptor activity’, Ylitalo et al (30) documented that it was involved in castrate-resistant PCa bone metastases. The regulation of androgen receptor activity was additionally discovered to be associated with therapy resistance and disease progression in PCa (31-33). Furthermore, transcription factor binding sites were additionally identified to be a crucial reaction domain in PCa, which may aid the explanation of the underlying regulatory mechanism (34,35). Regarding KEGG pathway analysis, Kojima et al (36) additionally revealed that ‘protein processing in the endoplasmic reticulum’ was a significant miR-143/145 regulated signal pathway in PCa, which may provide novel insights into the potential mechanism of PCa oncogenesis and metastasis. In summary, the enriched pathways, namely, the ‘androgen receptor signaling pathway’, ‘androgen receptor activity’, ‘transcription factor binding’ and ‘protein processing in the endoplasmic reticulum’ have been previously reported. The ‘androgen receptor signaling pathway’ has been implicated in the therapeutic strategies of PCa (27-29). Regarding the ‘androgen receptor activity’, Ylitalo et al (30) documented that it was involved in castrate-resistant PCa bone metastases. The regulation of androgen receptor activity was additionally discovered to be associated with therapy resistance and disease progression in PCa (31-33). Furthermore, transcription factor binding sites were additionally identified to be a crucial reaction domain in PCa, which may aid the explanation of the underlying regulatory mechanism (34,35). Regarding KEGG pathway analysis, Kojima et al (36) additionally revealed that ‘protein processing in the endoplasmic reticulum’ was a significant miR-143/145 regulated signal pathway in PCa, which may provide novel insights into the potential mechanism of PCa oncogenesis and metastasis. In summary, the enriched pathways, namely, the ‘androgen receptor signaling pathway’, ‘androgen receptor activity’, ‘transcription factor binding’ and ‘protein processing in the endoplasmic reticulum’ have been previously reported. 

Table III. Continued.

| E, ZWINT |Clinicopathological feature| n (mean ± SD) | t-test | P-value |
| --- | --- | --- | --- | --- |
| Age (years) | &lt;60 | 199 | 2.279±0.693 | -1.482 | 0.139 |
| Pathological T | T1+T2 | 186 | 0.960±0.405 | -6.195 | 0.000* |
| | T3+T4 | 298 | 1.243±0.599 | 0.000* |
| \*Statistically significant. miRNA/miR, microRNA; SD, standard deviation; PAICS, phosphoribosylaminomimidazole carboxylase and phosphoribosylaminomimidazolesuccinocarboxamide synthase; CDH1, cadherin 1; TWIST1, twist family bHLH transcription factor 1; ZWINT, ZW10 interacting kinetochore protein; KIAA0101, PCNA clamp associated factor. | | | | |

Table III. Continued.

| F, KIAA0101 |Clinicopathological feature| n (mean ± SD) | t-test | P-value |
| --- | --- | --- | --- | --- |
| Age (years) | &lt;60 | 199 | 1.067±0.506 | -2.284 | 0.023* |
| Pathological T | T1+T2 | 186 | 1.135±0.553 | 0.958 | 0.514 |
| | T3+T4 | 298 | 1.235±1.799 | 0.006* |

Using the PPI network, seven hub genes (PAICS, CDH1, SRC, TWIST1, ZWINT, KIAA0101 and AR) that may be the key target genes of miR-1 in PCa were identified. As miR-1 was downregulated in PCa, according to the meta-analysis, it was hypothesized that its target genes are upregulated accordingly. Thus, the expression of five hub genes was validated based on TCGA and GTEx data. It was identified that the five hub genes (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) were significantly upregulated in PCa. Since miR-1 was able to specifically bind to its targets, it was hypothesized that there is a correlation between miR-1 and its targets. As expected, there
was significant negative correlation between miR-1 expression, and PAICS, ZWINT and KIAA0101 expression. Regarding CDH1 and TWIST1, there was no significant correlation with miR-1. AR-dependent and castrate-resistant PCa may have different miRNA/mRNA expression profiles. Therefore, the expression of miR-1 and hub genes among AR-dependent, castrate-resistant PCa and normal tissues was investigated. In summary, it was identified that there was a trend that miR-1 was downregulated, while hub genes were upregulated in AR-dependent and castrate-resistant PCa compared with normal tissues. However, the expression difference of miR-1 and hub genes between AR-dependent and castrate-resistant PCa remains unclear. Studies with a larger sample size are required to elucidate the expression profiling alterations of miR-1/hub genes in AR-dependent and castrate-resistant PCa.

PAICS has been reported as a therapeutic target in breast cancer (38). Furthermore, increased PAICS was additionally identified to be associated with poor prognosis in lung cancer, which made it a promising prognostic biomarker (39). Cifola et al (40) first identified that PAICS was a mutated gene in melanoma. In the study conducted by Chakravarthi et al (41), the role of PAICS in the proliferation and invasion of PCa cell was evaluated, implying that PAICS was a therapeutic target. Collectively, PAICS may be a promising target in PCa. However, its association with miR-1 still requires experimental validation.

CDH1, additionally termed uvomorulin and CDHE, encodes a classical cadherin of the cadherin superfamily. Loss of or reduced expression of CDH1 is thought to contribute to more invasive tumors (42). A previous study discovered that CDH1 polymorphisms may be a prognostic indicator in non-metastatic laryngeal cancer (43). Jiao et al (44) identified that aberrant CDH1 was able to predict a poor prognosis for patients with pancreatic cancer. In addition, CDH1 was additionally identified to be associated with the risk of lung cancer (45), breast cancer (46), and gastric cancer (47), and may be a potential drug target. In PCa, there was additionally a meta-analysis that evaluated CDH1-60 C/A polymorphism as a risk factor in the development of PCa (48). In summary, CDH1 was a promising key target in PCa; however, it requires further experimental evaluation.

TWIST1 was reported to be implicated in cell lineage determination and differentiation. TWIST1 has been revealed to serve as an effective target for cancer metastasis and chemoresistance (49). In pancreatic cancer, TWIST1 was identified as a therapeutic target and prognostic marker for tumor metastasis (50). TWIST1 was additionally a target in lung cancer, which was correlated with the inhibition of proliferation, epithelial-mesenchymal transition and metastasis (51). Furthermore, overexpression of TWIST1...
was additionally identified to determine lung cancer chemoresistance and prognosis (52). TWIST1 was additionally documented to be associated with the invasion and metastasis of gastric cancer (53,54), and was a potential prognostic marker in colorectal cancer (55-57). Regarding PCa, numerous studies have reported that TWIST1 was involved in progression, including cancer invasion, migration and migration (58-63). As for the association between miR-1 and TWIST1, Chang et al (19) discovered that epidermal growth factor receptor translocation promotes the bone metastasis of PCa by downregulating miR-1, which directly increases the expression of TWIST1. Given the above information, TWIST1 may be considered a key target of miR-1 in PCa. This finding requires further experimental research to validate it.

ZWINT encodes a protein that is involved in kinetochore function. Xu et al (64) identified that ZWINT was increased in ovarian cancer and correlated with worse overall survival in patients with ovarian cancer. In bladder cancer, Ho et al (65) observed that ZWINT was associated with a cell proliferation marker. ZWINT was additionally identified to be significantly correlated with the clinical outcome of chronic lymphocytic leukemia (66). The association between ZWINT and PCa has not been reported in previously published literature. Further evidence is required to further elucidate the function of ZWINT in PCa.

KIAA0101 has been widely reported in the progression of various cancer types. For example, in hepatocellular carcinoma, overexpressed KIAA0101 was significantly associated with distant metastasis, advanced stage, early tumor recurrence and poor prognosis, which made it a potential therapeutic target (67-69). In gastric cancer, KIAA0101 was identified to be involved in the proliferation and invasion of PCa cells (70,71). In addition, overexpression of KIAA0101 was indicated to predict poor survival in lung cancer (72), esophageal cancer (73) and renal cancer (74). As for its role in PCa, to the best of our knowledge, no study at present has elucidated the association between KIAA0101 and PCa. Therefore, further studies are required to determine the precise role of KIAA0101 in PCa.

Collectively, it was identified that miR-1 was downregulated in PCa and was negatively correlated with PSA level. miR-1 was additionally associated with the tumor status, metastasis and lymph node metastasis of PCa. A total of seven hub genes, PAICS, CDH1, SRC, TWIST1, ZWINT, KIAA0101 and AR, were identified. Five of them (PAICS, CDH1, TWIST1, ZWINT and KIAA0101) were significantly upregulated in PCa and were negatively correlated with miR-1, which made them potential key target genes of downregulated miR-1 in PCa. The hub genes were associated with certain clinical features, including age, tumor status, residual tumor, lymph node metastasis, pathological T stage and PSA level. Using a review of published studies, further evidence was provided to support PAICS, CDH1 and TWIST1 as potential target genes of miR-1 in PCa. For ZWINT and KIAA0101, there is a lack of sufficient studies to demonstrate their role in PCa, and as such, they require further exploration. All the analyses in the present study were based on online database sources at the bioinformatics level. Therefore, further experimental studies are required to validate these genes. Nevertheless, the results obtained in the present study may aid the clinical diagnosis of PCa and provide insight into the molecular mechanisms of PCa.

Acknowledgements

Not applicable.

Funding

The present study was funded by the Promoting Project of Basic Capacity for Young and Middle-aged University Teachers in Guangxi (grant no. KY2016LX034). The funders had no role in study design, data collection and analysis, preparation of the manuscript, or decision to publish.

Availability of data and materials

All the data and materials used in the study are currently available at Pubmed (https://www.ncbi.nlm.nih.gov/pubmed/), GEO (https://www.ncbi.nlm.nih.gov/geo/), ArrayExpress (https://www.ebi.ac.uk/arrayexpress/), TCGA (https://cancergenome.nih.gov/), miRWalk 2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/), DAVID (https://david.ncifcrf.gov/) and STRING (https://string-db.org/) databases.

Authors' contributions

HB-Y, SH-L and GC designed the study and revised the manuscript. ZC-X, JC-H, LJ-Z, BL-G and DY-W contributed to the collection and analysis of the data, in addition to the writing of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin 67: 7-30, 2017.
2. Lavi A and Cohen M: Prostate cancer early detection using psa-current trends and recent updates. Harefuah 156: 185-188, 2017 (In Hebrew).
3. Filella X and Foj L: Prostate cancer detection and prognosis: From prostate specific antigen (PSA) to exosomal biomarkers. Int J Mol Sci 17: pii: E1784, 2016.
4. Kirby R: The role of PSA in detection and management of prostate cancer. Practitioner 290: 17-21, 3, 2016.
5. Bednarova S, Lindenberg ML, Vinsensia M, Zuiani C, Choyke PL and Turkbeby B: Positron emission tomography (PET) in primary prostate cancer staging and risk assessment. Transl Androl Urol 6: 413-423, 2017.
6. Wallis CJD, Haider MA and Nam RK: Role of mpMRI of the prostate in screening for prostate cancer. Transl Androl Urol 6: 464-471, 2017.
7. Johnson DC and Reiter RE: Multi-parametric magnetic resonance imaging as a management decision tool. Transl Androl Urol 6: 472-482, 2017.

8. Balascu I, Bragelmann J, Tudoran O, Feldea D, Balascu L, Anghel A, Sirbu IO, Scelamman E and Marian C: Urinary microRNAs for prostate cancer diagnosis, prognosis, and treatment response: Are we there yet? Wiley Interdiscip Rev RNA 8, 2017.

9. Martignoni F, Rossi L, Maugeri A, Gallà V, Conteduca V, De Giorgi U, Casadio V and Schepisi G: Urinary RNA-based biomarkers for prostate cancer detection. Clin Chim Acta 473: 96-105, 2017.

10. Mishra S, Yadav T and Rani V: Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol 98: 12-23, 2016.

11. Hua C, Shen JK, Horniczek FI, Kan Q and Duan Z: Regulation of microRNA-1 (miR-1) expression in human cancer. Biochim Biophys Acta Gene Regul Mech 1860: 227-232, 2017.

12. Rigaud VO, Ferreira LR, Ayub-Ferreira SM, Ando ET, Pimenta CC, Leite PV and Costa WP: miRWalk2.0: A comprehensive atlas of miRNA-target interactions. Dweep H and Gretz N: miRWalk2.0: A comprehensive atlas of miRNA-target interactions.

13. Anders S and Huber W: Differential expression analysis for sequencing data. Genome Biol 11: R106, 2010.

14. Dweep H and Gretz N: miRWalk2.0: A comprehensive atlas of microRNA-target interactions. Nat Methods 12: 697, 2015.

15. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of molecular interaction networks. Genome Res 13: 2498-2504, 2003.

16. Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45: W98-W102, 2017.

17. Pashaei E, Pashaei E, Ahmady M, Ozen M and Aydin N: Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy. PLoS One 12: e0179543, 2017.

18. Attard G, Richards J and de Bonjo JS: New strategies in metastatic prostate cancer: Targeting the androgen receptor signaling pathway. Clin Cancer Res 17: 1649-1657, 2011.

19. Wang L, Song G, Chang X, Tan W, Pan J, Zhu X, Liu Z, Mi Q, Yu J and Han B: The role of TNXDC5 in castration-resistant prostate cancer involvement of androgen receptor signaling pathway. Oncotarget 4: 34345-34354, 2013.

20. Yitale EO, Thyssell E, Jernberg E, Lundholm M, Cnalic S, Egevad L, Stattin P, Widsam A, Bergh A and Wikström P: Subgroups of castration-resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response. Eur Urol 71: 776-787, 2017.

21. Piut K, Périgea-González D, Vizzaccio JR, Andrade RP, Cárcano FM and Reis RM: Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. Oncotarget 7: 28891-28902, 2016.

22. Ware KE, Somarelli JA, Schaeffer D, Li J, Zhang T, Park S, Paterno SR, Freedman AS, Foo WC, Garcia-Blanco MA and Armstrong AJ: Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. Oncotarget 7: 50507-50521, 2016.

23. Wang Y, Ledet RJ, Imberg-Kazdan K, Logan SK and Garabedian MJ: Dynnein axonemal heavy chain 8 promotes androgen receptor activity and associates with prostate cancer progression. Oncotarget 7: 49268-49280, 2016.

24. Jiang J, Jia P, Shen B and Zhao Z: Top associated SNPs in prostate cancer are significantly enriched in cis-expression quantitative trait loci and at transcription factor binding sites. Oncotarget 5: 47177-47184, 2014.

25. Eisermann K, Tandon S, Bazarov A, Brett A, Fraizer G and Piontkivska H: Evolutionary conservation of zinc finger transcription factor binding sites in promoters of genes co-expressed with WT1 in prostate cancer. BMC Genomics 9: 337, 2008.

26. Kohli R, Singh R, Enokiya H, Fuchs KJ, Mizumoto T, Kinoshita T, Fuse M, Nishikawa R, Goto Y, Naya Y, et al: The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet 59: 78-87, 2014.

27. Li SX, Tong YP, Xie XC, Wang QH, Zhou HN, Han Y, Zhang ZY, Gao W, Li SG, Zhang XC and Bi RC: Octameric structure of the human bifunctional enzyme PAICS in purine biosynthesis. J Mol Biol 366: 1603-1614, 2007.

28. Gallenne T, Ross KN, Visser NL, Salomy, Desmet CJ, Wittner BS, Wessels LFA, Ramaswamy S and Peeper DS: Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer. Oncotarget 8: 20572-20587, 2017.

29. Goswami MT, Chen G, Chakravarthi BV, Pathi SS, Anand SK, Caraskadon SL, Giordano TJ, Chinnaiyan AM, Thomas DG, Palanisamy N, et al: Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. Oncotarget 6: 23445-23461, 2015.

30. Cifola I, Pietrelli A, Consolandi C, Severgini M, Mangano E, Russo V, De Bellis G and Battaglia C: Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic tumors by whole-exome sequencing and SNP array profiling. PLoS One 8: e63597, 2013.

31. Chakravarthi BV, Goswami MT, Pathi SS, Dodson M, Chandrashekar DS, Agarwal S, Nepal S, Hodigere Balasubramanya SA, Siddiqui J, Lonigro RJ, et al: Expression and role of PAICS, a novel purine biosynthetic gene in prostate cancer. Prostate 77: 10-21, 2017.

32. Gall TM and Frampton AE: Gene of the month: E-cadherin (CDH1). J Clin Pathol 66: 928-932, 2013.

33. Li D, Zhang R, Jin T, He N, Ren L, Zhang Z, Zhang Q, Xu R, Tao H, Zeng G and Gao J: ADHB and CDH1 polymorphisms predict prognosis in male patients with metastatic-laryngeal cancer. Oncotarget 7: 73216-73228, 2016.

34. Jiao F, Hu H, Han T, Zhuo M, Yuan C, Yang H, Wang L and Wang L: aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Oncotarget 7: 20572-20587, 2016.

35. Yu Q, Guo Q, Chen L and Liu S: Clinopathological significance and potential drug targeting of CDH1 in lung cancer: A meta-analysis and literature review. Drug Des Devel Ther 9: 2117-2118, 2015.

36. Huang R, Ding P and Yang F: Clinopathological significance and potential drug target of CDH1 in breast cancer: A meta-analysis and literature review. Drug Des Devel Ther 9: 5277-5285, 2015.

37. Zeng W, Zhu J, Shan L, Han Z, Aexiidings P, Qhau A, Zeng F, Liu Y and Li H: The clinopathological significance of CDH1 in gastric cancer: A meta-analysis and systematic review. Drug Des Devel Ther 9: 2149-2157, 2015.
Iqbal J, Aoun P, Armas-López L, Álvarez-Moran AM, 

Prostate cancer metastasis

Nugent K, Wang H, Taparra K, Lemtiri-Chlieh G, Yoon AR, Malek R, Gajula RP, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, et al: The twist box domain is required for Twist1-induced prostate cancer metastasis. Mol Cancer Res 11: 1387-1400, 2013.

Cho KH, Jeong KJ, Shin SC, Kang J, Park CG and Lee HY: STAT3 mediates TGF-β-induced Twist1 expression and prostate cancer invasion. Cancer Lett 336: 167-173, 2013.

Xu Z, Zhou Y, Cao Y, Dinh TL, Wan J and Zhao M: Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis. Med Oncol 33: 130, 2016.

Ho JR, Chapeaublanc E, Kirkwood L, Nicolle R, Benhamou S, Lebret T, Allory Y, Southgate J, Radvanyi F and Goud B: Deregulation of Rab and Rab effector genes in bladder cancer. PLoS One 7: e39469, 2012.

Gilling CE, Mittal AK, Chaturvedi NK, Iqbal J, Aoun PJ, Bierman PJ, Bociek RG, Weisenburger DD and Joshi SS: Lymph node-induced immune tolerance in chronic lymphocytic leukemia: A role for caveolin-1. Br J Haematol 158: 216-231, 2012.

Abdelgawad IA, Radwan NH and Hassanein HR: KIAA0101 mRNA expression in the peripheral blood of hepatocellular carcinoma patients: Association with some clinicopathological features. Clin Biochem 49: 787-791, 2016.

Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH and Hsu HC: Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res 13: 5368-5376, 2007.

Liu L, Liu Y, Chen X, Wang M, Zhou Y, Zhou P, Li W and Zhu F: Variant 2 of KIAA0101, antagonizing its oncogenic variant 1, might be a potential therapeutic strategy in hepatocellular carcinoma. Oncotarget 8: 43990-44003, 2017.

Zhu K, Diao D, Dang C, Shi L, Wang J, Yan R, Yuan D and Li K: Elevated KIAA0101 expression is a marker of recurrence in human gastric cancer. Cancer Sci 104: 353-359, 2013.

Zhang CF, Xia YH, Zheng QF, Li ZJ, Guo XH, Zhou HC, Zhang LL, Dong LP and Han Y: Effects of KIAA0101 expression on proliferation and invasion of gastric carcinoma MKN-45 cells. Zhonghua Bing Li Xue Za Zhi 41: 553-557, 2012 (In Chinese).

Kato T, Daigo Y, Ishikawa M, Sato M and Kaji M: Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients. Lung Cancer 75: 110-118, 2012.

Cheng Y, Li K, Diao D, Zhu K, Shi L, Zhang H, Yuan D, Guo Q, Wu X, Liu D and Dang C: Expression of KIAA0101 protein is associated with poor survival of esophageal cancer patients and resistance to cisplatin treatment in vitro. Lab Invest 93: 1276-1287, 2013.

Fan S, Li X, Tie L, Pan Y and Li X: KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin. Oncotarget 7: 13520-13537, 2016.